Correct Answer: D. Continue MDT, start systemic steroids
This question addresses the management of leprosy reactions, specifically Type 2 reaction (Erythema Nodosum Leprosum, ENL) or Type 1 reaction (reversal reaction) occurring during MDT. The key discriminator is that worsening of existing lesions with nerve involvement during active MDT indicates an immune-mediated reaction, NOT treatment failure or drug toxicity.
The correct approach is to continue MDT (which addresses the underlying mycobacterial load) while adding systemic corticosteroids to suppress the inflammatory reaction. This dual strategy is endorsed by WHO guidelines and Indian leprosy protocols (NLEP). Corticosteroids (typically prednisolone 0.5–1 mg/kg/day, tapered over 12 weeks) rapidly control inflammation, prevent nerve damage, and reduce disability. Continuing MDT ensures bacterial clearance; stopping it would allow relapse and perpetuate the disease.
Type 1 reactions (cell-mediated, occurring in borderline forms) and Type 2 reactions (immune complex-mediated, occurring in lepromatous/borderline lepromatous forms) both require corticosteroids as first-line anti-inflammatory therapy. Thalidomide is reserved for ENL (Type 2) refractory to steroids, not as initial therapy. The nerve involvement is a red flag for disability prevention—steroids must be started urgently to prevent permanent nerve damage, which is a major public health concern in Indian leprosy programs.
Why the other options are wrong
A. Continue MDT, start thalidomide — Thalidomide is NOT first-line for leprosy reactions. It is reserved for ENL (Type 2 reaction) refractory to corticosteroids after 2–4 weeks of steroid therapy. Starting thalidomide without steroids delays anti-inflammatory control and risks permanent nerve damage. Additionally, thalidomide requires strict teratogenicity precautions (IPLEDGE program equivalent in India) and is not indicated for Type 1 reactions at all. This is a common NBE trap—confusing second-line ENL therapy with initial reaction management. B. Stop MDT, start systemic corticosteroids — Stopping MDT is contraindicated and dangerous. Discontinuing anti-leprosy drugs allows relapse, permits continued bacterial multiplication, and prolongs infectivity. Leprosy reactions occur during active MDT due to immune reconstitution or antigen release—they are NOT a reason to abandon chemotherapy. NLEP guidelines explicitly state MDT must continue uninterrupted. Steroids alone without MDT will not cure leprosy and may mask disease progression. This option represents a fundamental misunderstanding of reaction pathophysiology. C. Stop MDT, start thalidomide — This combines two errors: stopping MDT (allowing relapse) and using thalidomide as monotherapy (inappropriate and ineffective). Thalidomide has no anti-mycobacterial activity and cannot replace MDT. This option would result in treatment failure, disease progression, and continued transmission. It violates both WHO and NLEP protocols. The presence of this option tests whether students understand that MDT is the backbone of leprosy treatment and cannot be abandoned regardless of reaction type.
High-Yield Facts
- Type 1 (reversal) reactions occur in borderline forms (BT, BL) during or after MDT; managed with corticosteroids alone (prednisolone 0.5–1 mg/kg/day × 12 weeks).
- Type 2 (ENL) reactions occur in LL/BL forms; first-line is corticosteroids; thalidomide (100–400 mg/day) reserved for steroid-refractory cases after 2–4 weeks.
- MDT must NEVER be stopped during leprosy reactions—continue full course while adding anti-inflammatory therapy to prevent relapse and nerve damage.
- Nerve involvement in reactions is a medical emergency requiring urgent corticosteroids to prevent permanent disability (Indian leprosy programs prioritize nerve damage prevention).
- Prednisolone dosing in reactions: 0.5–1 mg/kg/day, then taper by 5–10 mg every 2–4 weeks over 12 weeks; higher doses (1 mg/kg) for severe reactions with nerve involvement.
Mnemonics
**REACT (Leprosy Reaction Management) Reactions occur during MDT → Either Type 1 or Type 2 → Add corticosteroids (first-line) → Continue MDT uninterrupted → Thalidomide only if steroid-refractory ENL. Use this when deciding management of worsening lesions during treatment. MDT + Steroids = Rule** Never stop MDT for reactions. Always continue MDT + add steroids. Thalidomide is a later option, not initial. Helps students avoid the trap of stopping MDT or jumping to thalidomide.
NBE Trap
NBE pairs "worsening lesions during MDT" with thalidomide to lure students who confuse thalidomide (second-line ENL therapy) with initial reaction management. The trap is that thalidomide sounds "advanced" and students may think it's the answer for any severe reaction—but corticosteroids are always first-line, and MDT is never stopped.
Clinical Pearl
In Indian leprosy clinics, nerve involvement during reactions is a disability red flag—permanent nerve damage (lagophthalmos, claw hand, foot drop) is a major cause of leprosy-related disability. Starting high-dose steroids immediately (not waiting for thalidomide) is the difference between a patient who returns to work and one who becomes disabled. This is why NLEP emphasizes early steroid therapy in all reactions with nerve involvement.
_Reference: NLEP Guidelines (India), WHO Leprosy Elimination Programme; Robbins Ch. 8 (Infectious Diseases); Harrison Ch. 181 (Leprosy)_